We investigated whether autoantibodies against the human beta-adrenergic receptor (beta-AR) might be involved in cardiomyopathies secondary to valvular heart disease (VHD) or hypertensive heart disease (HHD).
Since the first reports on the detection of stimulating anti-beta-adrenergic receptor (anti-beta-AR) autoantibodies in patients with Chagas cardiomyopathy (1), a growing body of evidence suggests that autoimmunity to cardiac beta-ARs might be associated with several other human cardiomyopathies as well (2, 3) . Recently, we established a screening strategy for detecting functionally relevant antibeta-AR in patients suffering from dilated cardiomyopathy (DCM) or ischemic cardiomyopathy (ICM) by the use of recombinant intact human beta-AR expressed in various cell types (4) . Previously generated subtype-and domainspecific anti-beta-AR rabbit antibodies enabled us to define positive immunoreactions (5) . Confirming the results from earlier studies (2, 3) , in both DCM and ICM we detected a subset of patients with circulating immunoglobulin G (IgG) antibodies able to recognize native human beta-1-AR in a cell membrane and activate and/or sensitize these receptors through a direct (allosteric) receptor-antibody interaction. Their prevalence was 26% in DCM and 10% in ICM, respectively, and was associated with a significant reduction in cardiac function (4) .
However, in other kinds of heart disease also accompanied by reduced left ventricular function (and finally severe heart failure), the prevalence and possible implication of such activating anti-beta-1-AR remained to be evaluated. Consequently, in the present study, we used the newly established tools to screen the sera of 47 patients suffering from cardiomyopathies secondary to valvular (valvular heart disease [VHD] , n ϭ 28) or hypertensive heart disease ([HHD], n ϭ 19) for functionally active autoantibodies targeting the human beta-AR.
METHODS
Patients and sample acquisition. Forty-seven patients were recruited in the course of routine heart catheterization and coronary angiography: 28 patients suffered from chronic VHD (VHD subgroup; Table 1 ); 19 patients had a longlasting clinical history of hypertension (22 Ϯ 9 years) and suffered from advanced states of HHD (HHD subgroup). All patients had dyspnea corresponding to New York Heart Association functional classes II to IV, a left ventricular diastolic volume Ͼ110 ml/m 2 and an ejection fraction Ͻ55% (ventriculography). For HHD patients, significant coronary heart disease could be excluded by angiography, whereas three patients from the VHD subgroup had concomitant beginning (one-vessel disease, less than 50% stenosis), and one VHD patient had severe coronary artery disease but no prior infarction in clinical history. Because this patient had significant aortic valve stenosis (accompanied with severe aortic valve regurgitation) but no pathological Q-waves in the electrocardiogram, he was assigned to the VHD subgroup. At the time of sample acquisition, all patients were stable under therapy with diuretics, angiotensin converting enzyme inhibitors, digitalis or nitrates; five patients also received amlodipine. None was treated with beta-receptor blockers or beta-receptor agonists. One hundred eight healthy blood donors matched for gender (female/male ϭ 38/70) and age (48 Ϯ 18 years) served as controls (collective identical to our previous study [4] ). Table 2 summarizes the basic clinical and hemodynamic data of the patient subgroups analyzed.
IgG was prepared from the sera by caprylic acid precipitation; the concentration was determined by immunenephelometry (BN-II; Dade-Behring, Marburg, Germany), and for the assays, all samples were normalized to 1,000 g IgG/ml.
Immunoassays with synthetic antigens. For enzymelinked immunosorbent assay (ELISA), synthetic peptides corresponding to the second extracellular loop of the human beta-1-or beta-2-AR were synthesized commercially (ami- Data are mean values Ϯ SEM. Cont. ϭ contractility (peak dP/dt), and Relax. ϭ relaxation (peak negative dP/dt), both derived from left ventricular high fidelity time/pressure curves. CI ϭ cardiac index; EF angio ϭ left ventricular ejection fraction (ventriculography); HHD ϭ hypertensive heart disease; PVR ϭ pulmonary vascular resistance; SVR ϭ systemic vascular resistance; VHD ϭ valvular heart disease.
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no acids 195 to 225 or 169 to 200, according to the amino acid sequences of the human beta-1- [6] or beta-2-AR [7] , respectively). Amino-and carboxy-terminal fusion proteins of both receptor subtypes were produced in Escherichia coli as described previously (5), and fragments corresponding to the respective receptor-domains were isolated by highperformance liquid chromatography (HPLC) after thrombin digestion of the fusion products (to cleave off the bacterial fusion partner). Peptide (5 ng/well) or protein were coated onto 96-well microtiter plates (Maxisorb; Nunc, Kastrup, Denmark), incubated with two different IgG concentrations (25 and 12.5 g/ml, each in triplicate) for 12 h at 4°C and washed six times before the addition of biotinylated secondary rabbit anti-human IgG antibodies (1:5,000), streptavidin-peroxidase and o-phenylenediamine (Sigma, Deisenhofen, Germany). Optical densities were read at 490 nm.
Dot-blots were obtained using the same antigens as above, spotted onto activated nitrocellulose membranes (8) (Hybond C; Amersham, Buckinghamshire, UK). In addition to the selected receptor fragments, in this assay the IgG fractions were also checked against spots of bovine serum albumin (BSA) and a nonreceptor control peptide. The membranes were probed with 50 g/ml of the human IgG preparations for 2 h at 37°C, washed eight times and after incubation with horseradish peroxidase-conjugated goat anti-human IgG secondary antibodies, immunoreactive dots were visualized by enhanced chemiluminescence (ECL; Amersham).
Immunoassays with intact recombinant receptors.
Whole cell lysates or intact unfixed Sf9 insect cells infected with recombined baculovirus AcMNPV-beta-1-AR or -beta-2-AR transiently expressing 1 to 2 ϫ 10 6 human beta-1-or beta-2-AR (4,9) were utilized for native Western blotting and immunofluorescence studies. Wild-type virusinfected Sf9 cells served as negative controls. Presence of the receptor antigens was checked with previously characterized subtype-specific rabbit anti-beta-AR (positive control) (5). Sf9 cell lysates were subjected to native Western blotting as previously described (4, 10) and incubated with 50 g/ml of the patient IgG for 12 h at 4°C. Immunoreactive bands were visualized by enhanced chemiluminescence (see above).
Immunofluorescence experiments were performed on intact unfixed Sf9 cells, suspended in phosphate-buffered saline (PBS) containing 2 mmol/liter MgCl 2 and 2% BSA. The cells were incubated with human IgG fractions (167 and 83 g/ml) for 6 h at 4°C and then washed three times before the addition of CY3-labeled anti-human IgG secondary antibodies (Dianova, Hamburg, Germany) to detect receptor-bound patient IgGs. Fluorescence of the cells was inspected by a fluorescence microscope (400-fold magnification; Zeiss-Axioplan, Jena, Germany) and photographed with identical exposure times.
Assays on receptor-mediated cAMP accumulation. The cAMP assay was carried out on stably transfected Chinese hamster fibroblasts expressing 100 to 120 fmol/mg human beta-1-AR (CHW-beta-1 cells) (4). Cellular cAMP was determined by 125 I-labeled cAMP scintillation proximity assay (Biotrak Kit; Amersham) in three independent experiments. In brief, confluent cells were preincubated with 40 g IgG/ml from patients and healthy controls for 1 h at 37°C in the presence of 0.5 mmol/liter isobutylmethylxanthine. Subsequently, the cells were either stimulated with 10 mol/liter (Ϫ)isoproterenol or not, and incubation continued for 15 min at 37°C. After washing the cells two times with medium, cytoplasmic cAMP was extracted with boiling water, and the supernatants were directly used for the scintillation assay.
Statistical analysis. The threshold for a significantly increased reactivity in ELISA was based on the statistical distribution of n ϭ 108 gender-and age-matched healthy control subjects (mean Ϯ 2 SD). Statistical analysis of the cAMP assay was done by two-factorial ANOVA, using the experimental condition and the disease entity as factors 
RESULTS
Screening with synthetic beta-adrenergic receptor peptides. Sera of patients suffering from VHD or HHD and healthy controls were initially screened for IgG antibodies capable of binding to synthetic peptides corresponding to the aminoterminus, second extracellular loop, or carboxyterminus of human beta-1-and beta-2-AR, as previously described (4). An increased reactivity in ELISA was assumed for signals above the upper limit of the respective 95% confidence intervals (mean Ϯ 2 SD) of the healthy subjects. By this criterion, 36% of the patient IgG (39% of the VHD and 32% of the HHD subgroup) revealed increased reactivity with at least one of the selected receptor domains (Fig. 1, left) . Fifty-nine percent of the positive sera showed either multiple reactivity with different receptor domains (Fig. 1, numbers in parentheses) or cross-reactions between the beta-1-and beta-2-receptor subtype (Fig. 1,  hatched bars) . This high prevalence of multiple reactivity indicated either a polyclonal immune response against the whole receptor molecule or high levels of nonspecific binding.
In order to select IgG antibodies specifically binding to the above synthetic receptor fragments, all IgG fractions with increased reactivity in ELISA were further checked for nonspecific binding to BSA and to a nonreceptor control
Beta-receptor Antibodies in Cardiomyopathy peptide by dot-blotting (not shown). The number of patients still remaining antibody-positive indicated that more than half of the multiple reactions with several receptor domains were obviously due to nonspecific binding: 25% (n ϭ 7/28) and 11% (n ϭ 2/19) of the VHD and HHD patients, respectively, and less than 4% of the healthy subjects (n ϭ 4/108), had circulating antibodies specific for synthetic beta-AR domains. These immunoreactive IgGs were directed with similar frequency against all three domains tested and both beta-AR subtypes.
Immunofluorescence-studies on native human betaadrenergic receptors. Immunoreactive IgG specifically binding to synthetic receptor fragments was further checked for their capability of recognizing intact native human beta-AR. Only two of the patient IgG preparations (one from either subgroup) stained the membranes of Sf9 cells bearing beta-AR in their native conformation. These IgG antibodies were the ones directed against the second extracellular loop of the beta-1-AR subtype (anti-b1-ECII). However, none of the antibodies was able to recognize the receptors on renatured Western blots of Sf9 cell lysates, suggesting that anti-b1-ECII preferentially recognize a specific native receptor conformation that is sensitive to denaturation and cannot be completely restored after Western blotting. Figure 2 shows the typical membrane staining pattern of Sf9 cells transiently expressing human beta-1-(top) or beta-2-AR (middle) upon incubation with subtypespecific anti-beta-AR rabbit antibodies (Fig. 2 , rabbit antib1/2) (5). Wild-type virus-infected Sf9 cells not expressing beta-AR served as a negative control (bottom). Because these control cells were clearly (nonspecifically) stained by the immunoreactive IgG from the HHD patient, the membrane fluorescence pattern seen with beta-ARexpressing Sf9 cells was presumably not receptor-specific (Fig. 2, HHD) . Interestingly, further clinical examination of this patient revealed concomitant systemic lupus erythematosus accompanied with a high titer of antinuclear antibodies (ANA titer 1:3,200) but no anticardiolipin antibodies. In a singular instance, the IgG antibodies of one of the VHD patients, which according to ELISA and dot-blotting were directed against the beta-1-ECII peptide (but also revealed cross-reactivity with beta-1-N; see Fig. 1 , VHD, right), gave a fluorescence pattern similar to that obtained with anti-beta-1-AR rabbit antibodies (Fig. 2) . These IgGs had been isolated from a patient with moderate to severe 
combined aortic valve disease. However, left heart catheterization and coronary angiography revealed that this patient at the same time suffered from significant stenosis of the proximal left descendant anterior artery and of the proximal portion of the left circumflex artery. The ventriculogram showed diffuse reduction in wall motion, suggesting concomitant ischemic cardiomyopathy (left ventricular ejection fraction 15%; cardiac index 1.7 liters/min/m 2 ). None of the IgG preparations from healthy subjects who were not reacting with synthetic receptor peptides in ELISA (Fig. 2, Healthy) , or from patients and controls recognizing only the amino-and/or carboxyterminal receptor domains, stained native beta-AR expressed in Sf9 cells. However, 1 out of 108 healthy control subjects could be identified who had antibodies that recognized both the beta-1-ECII peptide and the native intact beta-1-AR expressed in Sf9 cells (Fig. 1, Healthy, right) . At the time of sample acquisition, this individual had no cardiac abnormalities (as assessed by echocardiography and electrocardiogram) and no pathological findings in the routine blood chemistry, including a screening for antinuclear antibodies.
Antibody effects on receptor-mediated cellular signaling.
All immunoreactive IgG fractions were also tested for possible functional effects by the use of stably transfected CHW-b1 cells. Only the IgG antibodies from the fluorescence-positive VHD patient and those from the only positive healthy control subject (able to recognize and to bind to native human beta-1-AR) affected receptormediated signaling (Fig. 3) . In the presence of these antibodies, basal cAMP levels were significantly increased by 1.48 Ϯ 0.08-(VHD patient) or 1.19 Ϯ 0.09-fold (Healthy positive), and isoproterenol-stimulated cAMP production was also increased by 1.39 Ϯ 0.14-or 1.09 Ϯ 0.04-fold, respectively (Fig. 3b) . These data confirm our previous findings, that functionally relevant human antibeta-1-AR may enhance receptor-mediated cAMP accumulation (4) . By contrast, the IgG preparations from all the other healthy controls (n ϭ 15) and patients (n ϭ 17) analyzed in the frame of the present study, including those of the HHD patient nonspecifically staining the membranes of beta-AR expressing Sf9 cells, had no effect on basal or agonist-stimulated cAMP production in repeated experiments (Fig. 3, Healthy negatives and HHD patient) .
DISCUSSION
The second extracellular loop of the beta-1-AR as autoantigen. Since the first reports on circulating antibeta-AR autoantibodies in cardiomyopathy, several groups have investigated the possible role and functional implication of receptor-directed autoimmune reactions in the development and/or course of human heart disease (2,3). However, depending on the respective screening strategies and immunological detection methods employed, the reports on the prevalence and/or functional impact of such receptor antibodies differed to some extent (2,3,11) . Recently, by using the molecular tools developed during the past few years (5-7,9), we were able to confirm the existence of functionally active human anti-beta-1-AR in a subgroup of patients suffering from DCM or ICM (4). Similar to those from the antibody-positive (VHD) patient in the present study, all of these antibodies were directed against the fairly small second extracellular loop domain of the human beta-1-AR (anti-beta-1-ECII), which is in agreement with previous findings from a Swedish group (2) . Although this loop is probably not directly involved in receptor-ligand binding (12) , because of its disulfidebonded cysteines, it might be important for the correct folding of the receptor molecule: 1) for ligand accessibility (13) or 2) for transition into an active receptor state (as demonstrated for the beta-2-AR [14] ). In addition, this loop has been shown to contain epitopes capable of stimulating immunoreactive B-and T-cells in vivo (15), which could explain its possible role as autoantigen.
The positive staining of beta-1-AR in native cells and the negative results of Western blots suggest that anti-b1-ECII antibodies preferentially bind to the receptor in its native conformation. Thereby, they appear to be able to increase both basal and isoproterenol-stimulated intracellular second messenger (cAMP) levels. Such functionally active antibeta-1-AR antibodies might act by promoting an active receptor conformation and, thus, sensitize the betaadrenergic system for catecholamines, which in a failing heart could further potentiate the vitious circle of adrenergic overdrive (16) . In agreement with this hypothesis, the only activating antibody-positive (VHD) patient identified 
